Completed
Oral 882C87 vs Acyclovir for Localized Herpes Zoster in Immunocompromised Patients
What is being tested
Netivudine
+ Acyclovir
Drug
Who is being recruted
Varicella Zoster Virus Infection+19
+ Blood-Borne Infections
+ Urogenital Diseases
Over 18 Years
+20 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 3
Interventional
Summary
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Patients are randomized to receive either 882C87 or acyclovir with corresponding placebos for 14 days, with two hundred patients in each of the two groups. They are stratified by presence or absence of HIV infection. Patients undergo 6 months of follow-up.
Principal SponsorGlaxo Wellcome
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
400 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Varicella Zoster Virus InfectionBlood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesDNA Virus InfectionsHerpesviridae InfectionsImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeAIDS-Related ComplexChickenpoxHerpes ZosterHIV Infections
Criteria
4 inclusion criteria required to participate
Ability to cooperate with the requirements of the study
Acute localized herpes zoster or rash present less than 72 hours, verified by clinical diagnosis
Immunocompromised condition primarily as a result of documented HIV infection, malignancy, chemotherapy or radiation therapy, solid organ or bone marrow transplant, or chronic immunosuppressive therapy
Life expectancy of at least 6 months
16 exclusion criteria prevent from participating
Acute, life-threatening condition
Capsaicin (Zostrix)
Drugs likely to interact with 882C87 (e.g., fluorouracil or flucytosine) within the past 7 days
Evidence of cutaneous or visceral dissemination (more than 20 discrete lesions outside adjacent dermatomes)
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 25 locations
SORRA / NC Research Ctr
Birmingham, United StatesUniv of Arizona / Univ Med Ctr
Tucson, United StatesCedars Sinai Med Ctr
Los Angeles, United StatesCompleted25 Study Centers